Show simple item record

dc.contributor.authorDíez Alarcia, Rebeca ORCID
dc.contributor.authorMuguruza Millán, Carolina ORCID
dc.contributor.authorRivero Calera, Guadalupe ORCID
dc.contributor.authorGarcía Bea, Aintzane
dc.contributor.authorGómez Vallejo, Vanessa
dc.contributor.authorCallado Hernando, Luis Felipe ORCID
dc.contributor.authorLlop Roig, Jordi ORCID
dc.contributor.authorMartín Muñoz, Abraham
dc.contributor.authorMeana Martínez, José Javier ORCID
dc.date.accessioned2021-06-10T08:45:19Z
dc.date.available2021-06-10T08:45:19Z
dc.date.issued2021-05-20
dc.identifier.citationTranslational Psychiatry 11 : (2021) // Article ID 302es_ES
dc.identifier.issn2158-3188
dc.identifier.urihttp://hdl.handle.net/10810/51824
dc.description.abstractThe status of serotonin 5HT2A receptors (5HT2ARs) in schizophrenia has been controversial. In vivo positron emission tomography neuroimaging and in vitro post-mortem binding studies have reported conflicting results about 5HT2AR density. Radiotracers bind different receptor conformations depending on their agonist, antagonist or inverse agonist properties. This study investigates 5HT2AR density in the post-mortem prefrontal cortex from subjects with schizophrenia and controls using three radiotracers with a different pharmacological profile. The specific binding parameters of the inverse agonist [18F]altanserin, the agonist [3 H]lysergic acid diethylamide (LSD) and the antagonist [ 3 H]MDL100907 to brain cortex membranes from 20 subjects with schizophrenia and 20 individually matched controls were evaluated under similar methodological conditions. Ten schizophrenia subjects were antipsychotic-free at death. Saturation curve analyses were performed by non-linear regression to obtain a maximal density of binding sites (Bmax) and the affinity of the respective radiotracers (Kd). In schizophrenia subjects, 5-HT2AR density was decreased when quantified by [18F]altanserin binding, whereas increased when evaluated by [3 H]LSD binding. However, [3 H] MDL100907 binding was unaltered. A slight loss of affinity (higher Kd) was observed exclusively in [3 H]LSD binding. The findings were more evident in antipsychotic-free subjects than in antipsychotic-treated subjects. In conclusion, a higher proportion of the 5-HT2AR-active functional conformation, which is rather identified by agonist radiotracers, was observed in schizophrenia patients. A consequent reduction of the inactive 5-HT2AR conformation, which is preferentially identified by inverse agonist radiotracers, was also obtained. Antagonist radiotracers do not distinguish between molecular conformations of the receptor, and accordingly, the absence of changes was shown. These results are compatible with the proposed increased functional activity of brain cortical 5-HT2ARs in schizophrenia.es_ES
dc.description.sponsorshipThis study was supported by the Spanish State Research Agency, Ministry of Science and ERD Funds (SAF-2009-08460, SAF-2017-88126-R, RYC-2017-22412 and CTQ-2017-87637-R), and the Basque Government (SAIOTEK S-PE13UN019 and IT-1211-19). Part of this work was conducted under the Maria de Maeztu Units of Excellence Programme (Grant MDM-2017-0720). C.M. and A.G.-B. were recipients of fellowships from the Marie Slodowska-Curie Programme (European Union’s Horizon 2020, Grant 747487) and the Basque Government predoctoral training Programme, respectivelyes_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/SAF-2017-88126-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/RYC-2017-22412es_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/CTQ-2017-87637-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/MDM-2017-0720es_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/747487es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectschizophreniaes_ES
dc.subject5HT2AR densityes_ES
dc.subjectprefrontal cortexes_ES
dc.subjectpharmacological profilees_ES
dc.subjectradiotracerses_ES
dc.titleOpposite Alterations of 5¬HT2A Receptor Brain Density in Subjects with Schizophrenia: Relevance of Radiotracers Pharmacological Profilees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0)es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.nature.com/articles/s41398-021-01430-7#Abs1es_ES
dc.identifier.doi10.1038/s41398-021-01430-7
dc.contributor.funderEuropean Commission
dc.departamentoesFarmacologíaes_ES
dc.departamentoeuFarmakologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0)
Except where otherwise noted, this item's license is described as This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0)